SOLIGENIX, INC. (SNGX)
About SOLIGENIX, INC.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $119.4K
- Net income
- -$11.1M
- Total assets
- $9.2M
- Market cap
- $6.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $11.8M
- Operating income
- -$11.8M
- Income tax
- -$506.6K
- Net income
- -$11.1M
- EPS (basic)
- $-2.14
- EPS (diluted)
- $-2.14
Balance sheet
- Total assets
- $9.2M
- Current assets
- $8.8M
- Total liabilities
- $3.9M
- Current liabilities
- $3.7M
- Shareholders’ equity
- $5.3M
Cash flow
- Operating cash flow
- -$10.3M
- Investing cash flow
- -$5.9K
- Financing cash flow
- $10.4M
- Net cash flow
- $116.6K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $6.6M
- EPS (diluted)
- $-2.14
- Shares outstanding
- 17.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 5, 1994
Soligenix, Inc. (SNGX) Stock Price
- Reported a net loss of $11.1M in FY2024.
- Trading 93% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SOLIGENIX, INC..
Write a review
News about SOLIGENIX, INC.
News & sentiment via Polygon.io
Soligenix, Inc.: frequently asked questions
Is Soligenix, Inc. an American company?
Soligenix, Inc. is a US-based company headquartered in Princeton, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Soligenix, Inc. headquartered?
Soligenix, Inc. is headquartered in Princeton, New Jersey, United States.
Is Soligenix, Inc. publicly traded?
Yes — Soligenix, Inc. is a publicly traded company. Its stock trades under the ticker symbol SNGX on the NASDAQ.
What does Soligenix, Inc. do?
Soligenix, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
